Dexpramipexole is ineffective in two models of ALS related neurodegeneration

PLoS ONE

Volumn 9, Issue 12, 2014, Pages

  Vieira, Fernando G ^a   LaDow, Eva ^b   Moreno, Andy ^a   Kidd, Joshua D ^a   Levine, Beth ^a   Thompson, Kenneth ^a   Gill, Alan ^a   Finkbeiner, Steven ^b,c,d   Perrin, Steven ^a  

^a ALS Therapy Development Institute   (United States)

^b GLADSTONE INSTITUTE OF NEUROLOGICAL DISEASE   (United States)

^c Hellman Family Foundation Program in Alzheimer's Disease Research   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COPPER ZINC SUPEROXIDE DISMUTASE; DEXPRAMIPEXOLE; TAR DNA BINDING PROTEIN; ANTIOXIDANT; BENZOTHIAZOLE DERIVATIVE; DNA BINDING PROTEIN; NEUROPROTECTIVE AGENT; PRAMIPEXOLE; SUPEROXIDE DISMUTASE; TDP-43 PROTEIN, HUMAN;

AMYOTROPHIC LATERAL SCLEROSIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BODY WEIGHT; BRAIN CELL; CELL SURVIVAL; CONTROLLED STUDY; DISEASE COURSE; DISEASE SEVERITY; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG RESPONSE; DRUG STABILITY; DRUG TREATMENT FAILURE; FEMALE; MALE; MOUSE; NERVE CELL NECROSIS; NERVE DEGENERATION; NONHUMAN; PROTEIN EXPRESSION; ANIMAL; C57BL MOUSE; CELL CULTURE; DRUG EFFECTS; GENETICS; HUMAN; LONG EVANS RAT; METABOLISM; NERVE CELL; RAT;

MUS; RATTUS;

AMYOTROPHIC LATERAL SCLEROSIS; ANIMALS; ANTIOXIDANTS; BENZOTHIAZOLES; CELLS, CULTURED; DNA-BINDING PROTEINS; HUMANS; MICE; MICE, INBRED C57BL; NEURONS; NEUROPROTECTIVE AGENTS; RATS; RATS, LONG-EVANS; SUPEROXIDE DISMUTASE;

EID: 84919626124     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0091608     Document Type: Article

References (28)

1. Rowland LP, Shneider NA (2001) Amyotrophic lateral sclerosis. New England Journal of Medicine 344: 1688-1700.
2. Miller RG, Rosenberg JA, Gelinas DF, Mitsumoto H, Newman D, et al. (2009) Practice Parameter update: The care of the patient with amyotrophic lateral sclerosis: Drug, nutritional, and respiratory therapies (an evidence-based review): Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 73: 1218-1226.
3. Miller RG, Rosenberg JA, Gelinas DF, Mitsumoto H, Newman D, et al. (2009) Practice Parameter update: The care of the patient with amyotrophic lateral sclerosis: Multidisciplinary care, symptom management, and cognitive/behavioral impairment (an evidence-based review): Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 73: 1227-1233.
4. Rosen DR, Siddique T, Patterson D, Figlewics DA, Sapp PC, et al. (1993) Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature 362: 59-62.
5. Ludolph AC, Bendotti C, Blaugrund E, Chio A, Greensmith L, et al. (2010) Guidelines for preclinical animal research in ALS/MND: A consensus meeting. Amyotrophic Lateral Sclerosis 11: 38-45.
6. Scott S, Kranz JE, Cole J, Lincecum JM, Thompson K, et al. (2008) Design, power, and interpretation of studies in the standard murine model of ALS. Amyotrophic Lateral Sclerosis 9: 4-15.
7. Neumann M, Sampathu DM, Kwong LK, Traux AC, Micsenyl MC, et al. (2006) Ubiquitinated TDP-43 in Frontotemporal Lobar Degeneration and Amyotrophic Lateral Sclerosis. Science 314: 130-133.
8. Chen-Plotkin AS, Lee VMY, Trojanowski JQ (2010) TAR DNA-binding protein 43 in neurodegenerative disease. Nat Rev Neurol 6: 211-220.
9. Mackenzie IR, Rademakers R, Neumann M (2010) TDP-43 and FUS in amyotrophic lateral sclerosis and frontotemporal dementia. The Lancet Neurology 9: 995-1007
10. Hatzipetros T, Bogdanik LP, Tassinari VR, Kidd JD, Moreno AJ, et al. (2013) C57BL/6J congenic Prp-TDP43A315T mice develop progressive neurodegeneration in the myenteric plexus of the colon without exhibiting key features of ALS. Brain Research 1-14. doi:10.1016/j.brainres.2013.10.013
11. Barmada SJ, Skibinski G, Korb E, Rao EJ, Wu JY, et al. (2010) Cytoplasmic Mislocalization of TDP43 is toxic to neurons and enhanced by a mutation associated with familial amyotrophic lateral sclerosis. Journal of Neuroscience 30: 639-349.
12. Serio A, Bilican B, Barmada SJ, Ando DM, Zhao C, et al. (2013) Astrocyte pathology and the absence of non-cell autonomy in an induced pluripotent stem cell model of TDP-43 proteinopathy. Proceedings of the National Academy of Sciences 1-6. doi:10.1073/pnas.1300398110/-/DCSupplemental
13. Daub A, Sharma P, Finkbeiner S (2009) High-content screening of primary neurons: ready for prime time. Current Opinion in Neurobiology 19: 537-543
14. Benatar M (2007) Lost in translation: Treatment trials in the SOD1 mouse and in human ALS. Neurobiology of Disease 26: 1-13.
15. Gordon PH (2013) Amyotrophic Lateral Sclerosis: An update for 2013 Clinical Features, Pathophysiology, Management and Therapeutic Trials. A&D 04: 295-310.
16. Cudkowicz ME, van den Berg LH, Shefner J, Mitsumoto H, Mora JS, et al. (2013) Dexpramipexole versus placebo for patients with amyotrophic lateral sclerosis (EMPOWER): a randomised, double-blind, phase 3 trial. The Lancet Neurology 1-9. doi:10.1016/S1474-4422(13)70221-7
17. Ferrari-Toninelli G, Maccarinelli G, Uberti D, Buerger E, Memo M (2010) Mitochondria-targeted antioxidant effects of S(-) and R(+) pramipexole. BMC Pharmacol 10: 2.
18. Cassarino DS, Fall CP, Smith TS, Bennett JPJ (1998) Pramipexole Reduces Reactive Oxygen Species. Journal of Neurochemistry 71: 295-301.
19. Alavian KN, Dworetzky SI, Bonanni L, Zhang P, Sacchetti S, et al. (2012) Effects of dexpramipexole on brain mitochondrial conductances and cellular bioenergetic efficiency. Brain Research 1446: 1-11.
20. Gordon P and Corcia P (2012) Amyotrophic lateral sclerosis and the clinical potential of dexpramipexole. TCRM 359. doi:10.2147/TCRM.S21981
21. Chang WL, Weber M, Breier MR, SaintMarie RL, Hines SR, et al. (2012) Stereochemical and neuroanatomical selectivity of pramipexole effects on sensorimotor gating in rats. Brain Research 1437: 69-76.
22. Bozik ME, Mather JL, Kramer WG, Gribkoff VK, Ingersoll EW Safety (2011) Tolerability, and Pharmacokinetics of KNS-760704 (Dexpramipexole) in Healthy Adult Subjects. The Journal of Clinical Pharmacology 51: 1177-1185.
23. Cudkowicz M, Bozik ME, Ingersoll EW, Miller, Mitsumoto H, et al. (2011) The effects of dexpramipexole (KNS-760704) in individuals with amyotrophic lateral sclerosis. Nat Med 17: 1652-1656.
24. Danzeisen R, Schwalenstoecker B, Gillardon F, Buerger E, Krzykalla, et al. (2006) Targeted antioxidative and neuroprotective properties of the dopamine agonist pramipexole and its nondopaminergic enantiomer SND919CL2x [(+) 2-amino-4, 5, 6, 7-tetrahydro-6-Lpropylaminobenzathiazole dihydrochloride]. Journal of Pharmacology and Experimental Therapeutics 316: 189-199.
25. Alexander GM, Erwin KL, Byers N, Deitch JS, Augelli BJ, et al. (2004) Effect of transgene copy number on survival in the G93A SOD1 transgenic mouse model of ALS. Molecular Brain Research 130: 7-15.
26. Gill A, Kidd J, Vieira F, Thompson K, Perrin S (2009) No Benefit from Chronic Lithium Dosing in a Sibling-Matched, Gender Balanced, Investigator-Blinded Trial Using a Standard Mouse Model of Familial ALS. PLoS ONE 4: e6489.
27. Lincecum JM, Vieira FG, Wang MZ, Thompson K, DeZutter GS, et al. (2010) From transcriptome analysis to therapeutic anti-CD40L treatment in the SOD1 model of amyotrophic lateral sclerosis. Nat Genet 42: 392-399.
28. Matthews JN, Altman DG, Campbell MJ, Royston P (1990) Analysis of serial measurements in medical research. BMJ 300: 230-235.